Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Targeting SARS-CoV-2 papain-like protease in the postvaccine era

AT Ton, M Pandey, JR Smith, F Ban… - Trends in …, 2022 - cell.com
While vaccines remain at the forefront of global healthcare responses, pioneering
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

Y Lu, Q Yang, T Ran, G Zhang, W Li, P Zhou… - Nature …, 2024 - nature.com
The RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CLpro), and papain-like
protease (PLpro) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as …

Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target

B Qin, Z Li, K Tang, T Wang, Y **e, S Aumonier… - Nature …, 2023 - nature.com
Abstract SARS-CoV-2 nsp3 is essential for viral replication and host responses. The SARS-
unique domain (SUD) of nsp3 exerts its function through binding to viral and host proteins …

COVID-19 drug discovery and treatment options

JFW Chan, S Yuan, H Chu, S Sridhar… - Nature Reviews …, 2024 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …

Targeting papain-like protease by natural products as novel therapeutic potential SARS-CoV-2

M Waqas, S Ullah, SA Halim, NU Rehman, A Ali… - International Journal of …, 2024 - Elsevier
The highly infectious respiratory illness 'COVID-19'was caused by SARS-CoV-2 and is
responsible for millions of deaths. SARS-single-stranded viral RNA genome encodes …

Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity

GR Velma, Z Shen, C Holberg, J Fu… - Journal of Medicinal …, 2024 - ACS Publications
The SARS-CoV-2 papain-like protease (PLpro), essential for viral processing and immune
response disruption, is a promising target for treating acute infection of SARS-CoV-2. To …

SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads

AK Ghosh, D Shahabi, MEC Imhoff, S Kovela… - Bioorganic & Medicinal …, 2023 - Elsevier
We report here the synthesis and biological evaluation of a series of small molecule SARS-
CoV-2 PLpro inhibitors. We compared the activity of selected compounds in both SARS-CoV …

Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2

LV Yevsieieva, KO Lohachova, A Kyrychenko… - RSC …, 2023 - pubs.rsc.org
The pandemic caused by the coronavirus SARS-CoV-2 led to a global crisis in the world
healthcare system. Despite some progress in the creation of antiviral vaccines and mass …

A Mini-Review on the Common Antiviral Drug Targets of Coronavirus

J Wang, Q Zhu, X **ng, D Sun - Microorganisms, 2024 - mdpi.com
Coronaviruses in general are a zoonotic pathogen with significant cross-species
transmission. They are widely distributed in nature and have recently become a major threat …